Beijing Han Mei Pharmaceutical Co., Ltd.

BEIJING Korea-US Pharmaceutical Co., Ltd. is Korea's first modern pharmaceutical enterprise investment in China, was founded in March 1996, Korea and the United States Pharmaceutical Industry Co., Ltd., Beijing Zi Zhu Pharmaceutical (formerly Beijing Third Pharmaceutical Factory) and Beijing Tianzhu Airport Industrial Development company co-investment in the construction of pharmaceutical enterprises. Company headquarters and GMP Pharmaceutical Factory is located in Beijing.

BEIJING Korea-US Research and Development Center was established in 2008, after more than a year of rapid development, has a mature research and development team, most of them graduated from Peking University, Tsinghua University, Chinese Academy of Sciences and Military Academy and other well-known institutions of higher learning and research institutes, of which more than 90% have a master's degree, of which 20% have a doctorate, There are many returning scholars and employees with years of working experience.Beijing Korea-US Research and Development centerThe research center covers nearly 4000 square meters, including biological laboratories, chemical synthesis laboratories and pharmacological toxicology laboratories. We start from the design and renovation of high standards, strict requirements, and strive to establish a world-class research center. The research center is equipped with nuclear magnetic, LCMS, Lcms/ms,techan, Agilent HPLC and other world-class drug research equipment. BEIJING Korea-US Research center of the technology from Korea and the United States Research Center, the biological aspects of the main focus on long-acting recombinant protein and long-acting peptide development, chemistry is mainly the development of oral small molecule anticancer drugs, Korea and the United States medicine has the 2 technology platform of the PCT patent, can be developed in these 2 platforms a lot of drugs, Several drugs have been introduced into Phase I/ii clinical trials in the United States and South Korea.Beijing Korea-US Research and Development centerBiological GroupThe biological groups are divided into 6 groups, such as molecular cloning, cell line screening, mass production, protein engineering, biological analysis, and drug generation and testing. The recombinant protein source has 4 expression platforms of prokaryotic, mammal, insect and yeast. Polypeptide has the ability to design, modify and synthesize various peptides.Small molecule drug synthesis GroupStudies in the small molecule drug synthesis group include anticancer drugs that act on apoptosis pathways, small molecule kinase inhibitors, and antitumor drugs that act on other targets. Project-based, each project team includes chemical synthesis, computer-aided design, analysis, pharmacology, and pharmacokinetic and other disciplines.Pharmacological Toxicology GroupPharmacological toxicology group mainly for the latest research and development of products for multi-directional evaluation, and in the process of chemical drug research project is responsible for the investigation and part of the feasibility analysis work. Several drug-in vitro screening platforms have been established to successfully build 4 models of tumor-bearing mice, openBeijing Han Mei Pharmaceutical Co., Ltd.Drug metabolism research, anti-tumor efficacy research, drug safety evaluation and many other experiments. The research center has 3 related results to prepare for patent application.  With the growth of the Beijing Korea-US Research Center, our research direction will be more comprehensive in the future, closely follow the international trend, in order to develop more products with independent intellectual property rights. Product http://www.bjhanmi.com.cn/front/cn/cpzx_center.jsp

Beijing Han Mei Pharmaceutical Co., Ltd.